contact us krjpencn

서비스분야

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

현재 위치: > Services & Solutions > Integrated Projects > Rodent Cerebrovascul...

Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.

Range of Cerebrovascular Disease

Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.

Disease
ICD 10
Models
Intracerebral hemorrhage I60-I62 Intracranial Autologous Blood Injection,Subarachnoid hemorrhage
Cerebral infarction I63 Ischemic stroke model
Stroke I64
Cerebral thrombosis I65
Cerebral Embolism I66
Other I67-I69 Other

The annual treatment cost of cardiovascular and cerebrovascular diseases in China is RMB 540.6 billion. The annual treatment cost of cerebrovascular diseases accounts for 25.68% of cardiovascular and cerebrovascular diseases. Among them, ischemic stroke accounts for 18% and hemorrhagic stroke accounts for 7%.

cardiovascular and cerebrovascular diseases models

Advantages of Medicilon MCAO Model Evaluation System

• Rat and mouse MCAO models with stable lesions, high success rate and high survival rate

• Reliable and effective evaluation of dose-effect/time-effect relationship

• Efficacy evaluation of transient cerebral ischemia and permanent cerebral ischemia

• Complete the investigation of various pharmacodynamic core indicators according to STAIR technical guidelines

• The model rodents could be customized with special diseases and complete activity evaluations according to customer requirements

MCAO Mouse Model Evaluation System - Investigation of Dose-Response and Time-Response Relationship

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 1 h to achieve reperfusion.

• Dose-Response Investigation: Animals were given the positive drug Xianbisxin 20, 10, 1, 0.1 and 0.01 mg/kg intravenously at 0.5h after infarction, respectively, and the dose-effect relationship was investigated.

• Time-Response Investigation: Animals were given the positive drug Xianbixin 20mg/kg intravenously at 0.5h after infarction and 2h, 6h, 8h and 10h after reperfusion respectively, and the time-effect relationship was investigated.

Inspection indicators

The infarct volume was measured by TTC method, and the brain water content was measured by drying method.

Evaluation of the MCAO Mouse Model - Dose-Response Relationship

Dose-Effect Relationship Study (TTC and brain water content) (mean±SEM)

Dose-Effect Relationship Study (TTC and brain water content) (mean±SEM)

Evaluation of the MCAO Mouse Model - Time-Response Relationship

Time-Effect Relationship Study (TTC and brain water content) (mean±SEM)

Time-Effect Relationship Study (TTC and brain water content) (mean±SEM)

MCAO Mouse Model Evaluation System - Trement Time Window Investigation

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after 1h, 2h and 4h of blocking to achieve reperfusion.

• Treatment Time Window Investigation: Animals were intravenously injected with the positive drug Xianbixin 20mg/kg 0.5h after infarction, and the treatment time window was investigated.

Inspection indicators

Infarct volume was measured by TTC method, brain volume by drainage method, and brain water content by drying method.

Result

Treatment Time Window Investigation A: TTC; B: Brain Volume, C: Brain Water Content (mean±SEM)

Treatment Time Window Investigation

MCAO Mouse Model Evaluation System - Neurological Recovery Investigation

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 1 h to achieve reperfusion.

• Neurological Recovery Investigation: Animals were intravenously injected with the positive drug Xianbixin 20mg/kg 0.5h after infarction, and the treatment time window was investigated.

Inspection indicators

Zea-longa score, Balance Beam Transit Time, Rotarod Dwell Time, Grip Strength

MCAO Mouse Model Evaluation System-Investigation of Neurological Function

Pharmacodynamic Investigation of Neurological Function: A: Zea-longa score; B: Balance Beam Transit Time

Pharmacodynamic Investigation of Neurological Function

Pharmacodynamic Investigation of Neurological Function: C: Rotarod Dwell Time; D: Grip Strength

Pharmacodynamic Investigation of Neurological Function

MCAO Rat Model Evaluation System

Animals: SD Rat, male

Group: Control Group, Model Group, Positive Drug Group 1 (Edaravone), Positive Drug Group 2 (Nimodipine)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 2h to achieve reperfusion.

• Pharmacodynamics Study: Animals were given the positive drugs by intravenous injection at 0.5h after infarction, and the pharmacodynamic effects of the two positive drugs were investigated.

Inspection indicators

Zea-longa score, Infarct Volume by TTC method

Result-1: Behavioral Scores of Rats

Behavioral Scores of Rats

Rat Behavioural Examination (Zea-longa Score and Animal Behaviour)

Rat Behavioural Examination (Zea-longa Score and Animal Behaviour)

Result-2:TTC Staining of Brain

Cerebral Infarction Volume Investigation (TTC staining and infarct volume ratio)

Cerebral Infarction Volume Investigation (TTC staining and infarct volume ratio)

Other articles you maybe interested:

1. Novel Parkinson's Therapies Possible with New Mouse Model

2. New Player in Alzheimer’s Disease Pathogenesis Identified

3. Neuropathic Pain Eased by Novel Light-Based Technique

4. MS Drug Slows Brain Shrinkage by Nearly Half

관련 실험실